ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926

Its studies are mostly in Carcinoma, Hepatocellular, led by Bayer.

Furthest: phase 1, since Dec 18, 20241 company-led study, 1 open or runningNext primary completion: Jul 31, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer11 open or runningphase 1since Dec 18, 2024Dec 18, 2024Jul 31, 2029phase 1 · NCT06764316

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2024First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT06764316 · 148 planned · United States, Belgium, Canada and more

Ahead

  1. Jul 31, 2029Primary completion: phase 1 study in Carcinoma, HepatocellularNCT06764316

TargetBeta

GPC3 →read by rule
“A radioimmunoconjugate composed of a high-affinity antibody targeting glypican-3 (GPC3; GPC-3) ”NCIt, by rule

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
codrituzumabHoffmann-La Rochephase 23
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 22
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 11
ACE723ruleacepodia-biotech-incphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06764316Carcinoma, Hepatocellular · United States, Belgium, Canada and more1RecruitingJul 31, 2029148

How it is read

Names in the registry

  • “BAY 3547926”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.